West Pharmaceutical Services (NYSE:WST) Posts Quarterly Earnings Results, Beats Estimates By $0.29 EPS

West Pharmaceutical Services (NYSE:WST) released its earnings results on Thursday. The medical instruments supplier reported $2.37 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $2.08 by $0.29, Zacks reports. West Pharmaceutical Services had a return on equity of 19.03% and a net margin of 16.85%.The business had revenue of $872.30 million for the quarter, compared to the consensus estimate of $839.98 million. During the same quarter in the previous year, the business earned $1.84 earnings per share. West Pharmaceutical Services’s quarterly revenue was up 13.8% on a year-over-year basis. West Pharmaceutical Services updated its Q3 2026 guidance to 2.140-2.240 EPS and its FY 2026 guidance to 8.850-9.050 EPS.

Here are the key takeaways from West Pharmaceutical Services’ conference call:

• West delivered Q2 2026 results above expectations, with revenue of $872 million up 13% organically and adjusted EPS of $2.37 up 29% year over year.
• The company raised full-year guidance to 10%-11% organic revenue growth and adjusted EPS of $8.85-$9.05, citing strong momentum in the business.
• High-value product components were the main growth engine, with organic growth of 18% led by biologics, Annex 1-related upgrades, and GLP-1 demand. Management said non-GLP-1 HVP components outperformed expectations and still have a multi-year runway.
• The cyber incident still affected West Vantage, holding Q2 growth to 1% and shifting some revenue into the second half. Management said the impact should be made up later this year, with Q3 expected to be the trough for the segment.
• Gross margin and operating margin both improved meaningfully in the quarter, helped by stronger sales mix, pricing, and leverage from higher revenue. West also continued share repurchases, buying back $157 million of stock in Q2.

West Pharmaceutical Services Trading Down 4.3%

Shares of NYSE:WST opened at $340.15 on Friday. The company has a debt-to-equity ratio of 0.07, a current ratio of 2.71 and a quick ratio of 2.04. West Pharmaceutical Services has a 1 year low of $223.83 and a 1 year high of $386.00. The company has a market cap of $24.03 billion, a P/E ratio of 45.56, a PEG ratio of 2.90 and a beta of 1.16. The stock’s fifty day moving average price is $336.51 and its 200-day moving average price is $287.14.

West Pharmaceutical Services Dividend Announcement

The company also recently disclosed a quarterly dividend, which will be paid on Wednesday, August 5th. Shareholders of record on Wednesday, July 29th will be given a dividend of $0.22 per share. This represents a $0.88 annualized dividend and a yield of 0.3%. The ex-dividend date of this dividend is Wednesday, July 29th. West Pharmaceutical Services’s payout ratio is presently 11.76%.

West Pharmaceutical Services News Summary

Here are the key news stories impacting West Pharmaceutical Services this week:

• Positive Sentiment: West Pharmaceutical posted Q2 adjusted EPS of $2.37, topping estimates of $2.08, and revenue of $872.3 million versus $840.0 million expected, signaling a solid quarter across the business. West Reports Second-Quarter 2026 Results
• Positive Sentiment: The company raised full-year 2026 EPS guidance to $8.85-$9.05 and revenue guidance to $3.3 billion-$3.4 billion, both ahead of consensus, reinforcing confidence in the outlook. Reuters article on raised forecast
• Positive Sentiment: Management highlighted strong demand tied to injectable medicines, including GLP-1, diabetes, and obesity treatments, with high-value product growth driving the upbeat results and guidance increase. TipRanks guidance article
• Neutral Sentiment: West also issued Q3 guidance above estimates, with EPS of $2.14-$2.24 and revenue of $820 million-$835 million, which supports near-term visibility but was broadly in line with the strong quarter already reported.

Analyst Upgrades and Downgrades

A number of research analysts recently commented on the company. KeyCorp raised their price target on West Pharmaceutical Services from $350.00 to $390.00 and gave the stock an “overweight” rating in a research report on Thursday, July 2nd. Stephens reaffirmed an “overweight” rating and set a $360.00 target price on shares of West Pharmaceutical Services in a report on Tuesday, June 2nd. Zacks Research raised West Pharmaceutical Services from a “hold” rating to a “strong-buy” rating in a research note on Wednesday, May 13th. Morgan Stanley increased their target price on shares of West Pharmaceutical Services from $325.00 to $365.00 and gave the company an “equal weight” rating in a research report on Thursday, July 9th. Finally, Weiss Ratings upgraded shares of West Pharmaceutical Services from a “hold (c-)” rating to a “hold (c)” rating in a research report on Monday, April 27th. Two research analysts have rated the stock with a Strong Buy rating, eleven have issued a Buy rating and two have issued a Hold rating to the company. According to MarketBeat.com, the stock has an average rating of “Buy” and a consensus price target of $363.17.

Insider Activity at West Pharmaceutical Services

In other West Pharmaceutical Services news, CAO Chad Winters sold 896 shares of West Pharmaceutical Services stock in a transaction on Monday, April 27th. The stock was sold at an average price of $300.67, for a total transaction of $269,400.32. Following the completion of the sale, the chief accounting officer directly owned 1,523 shares of the company’s stock, valued at $457,920.41. The trade was a 37.04% decrease in their position. The sale was disclosed in a document filed with the SEC, which is available at this hyperlink. Also, VP Annette F. Favorite sold 2,817 shares of the business’s stock in a transaction that occurred on Monday, April 27th. The stock was sold at an average price of $305.20, for a total transaction of $859,748.40. Following the completion of the transaction, the vice president directly owned 16,828 shares of the company’s stock, valued at $5,135,905.60. This trade represents a 14.34% decrease in their position. Additional details regarding this sale are available in the official SEC disclosure. Insiders own 0.60% of the company’s stock.

Institutional Investors Weigh In On West Pharmaceutical Services

Institutional investors and hedge funds have recently modified their holdings of the company. Zions Bancorporation National Association UT boosted its position in West Pharmaceutical Services by 25.3% during the fourth quarter. Zions Bancorporation National Association UT now owns 312 shares of the medical instruments supplier’s stock worth $86,000 after purchasing an additional 63 shares in the last quarter. Erste Asset Management GmbH purchased a new stake in shares of West Pharmaceutical Services in the fourth quarter valued at approximately $207,000. Knollwood Investment Advisory LLC acquired a new position in shares of West Pharmaceutical Services during the 3rd quarter worth approximately $220,000. Ausdal Financial Partners Inc. acquired a new position in shares of West Pharmaceutical Services during the 3rd quarter worth approximately $220,000. Finally, Brooklyn Investment Group lifted its position in shares of West Pharmaceutical Services by 81.3% during the 3rd quarter. Brooklyn Investment Group now owns 816 shares of the medical instruments supplier’s stock valued at $214,000 after buying an additional 366 shares in the last quarter. Institutional investors and hedge funds own 93.90% of the company’s stock.

West Pharmaceutical Services Company Profile

West Pharmaceutical Services, Inc is a global developer and manufacturer of components, systems and services that enable the containment and delivery of injectable drugs. The company focuses on high-quality packaging and delivery solutions for the pharmaceutical and biotech industries, producing primary drug packaging components and specialized drug delivery devices used for vaccines, biologics and other injectable therapies. West is known for its elastomeric closures, seals and polymer components that maintain sterility and compatibility with sensitive drug formulations.

In addition to component manufacturing, West provides engineered delivery systems and support services across the product lifecycle.